BioCentury
ARTICLE | Clinical News

Entresto sacubitril/valsartan regulatory update

October 5, 2015 7:00 AM UTC

EMA’s CHMP recommended approval of Entresto sacubitril/valsartan from Novartis to treat adults with symptomatic chronic heart failure (CHF) with reduced ejection fraction. The pharma expects a decision from the European Commission by year end. The crystalline complex of valsartan and sacubitril in an equimolar ratio is under accelerated review in the EU. Valsartan is an antagonist of angiotensin II type 1 (AT1) receptor (ATGR1), and sacubitril is an inhibitor of neutral endopeptidase ( neprilysin; MME; NEP; CD10). ...